Group 1 - The Hang Seng Index initially expanded its gains to 1%, while the Hang Seng Tech Index rose by 1.06% [1] - The biopharmaceutical, innovative drug, and pharmaceutical outsourcing sectors showed strong performance [1] - Chip stocks have been rising for several consecutive days, and Chinese brokerage stocks continued their upward trend [1] Group 2 - Guotai Junan International (01788.HK) increased by over 7%, while Kelaiying (06821.HK) surged by over 16% [1] - Yesterday's popular stock, Puxing Energy (00090.HK), rose by over 22% [1]

Group 1 - The A-share pharmaceutical sector showed strong performance in the morning session, with notable gains in CRO, biopharmaceuticals, and innovative drugs [1] - Kangchen Pharmaceutical reached the daily limit increase, while Anke Bio surged over 6% [1] - Other stocks such as Kangtai Biological, Zhifei Biological, and Ganli Pharmaceutical also experienced upward movement [1]

Group 1 - The A-share pharmaceutical sector experienced a strong upward trend in early trading, with significant gains in concepts such as CRO, recombinant proteins, and innovative drugs [1] - Companies like Medisi saw an increase of over 16%, while Bid Pharma rose more than 7%, with other stocks like Zhaoyan New Drug, Sunshine Nuohuo, and Nossger also following suit [1] - The National Development and Reform Commission announced that since the 14th Five-Year Plan, 402 new drugs have been added to the national medical insurance drug list [1]

Group 1 - The A-share pharmaceutical sector has collectively rebounded, with concepts such as recombinant proteins, CRO, biopharmaceuticals, and innovative drugs showing reduced declines [1] - Jinbo Bio has seen an increase of over 3%, with stocks like Shanghai Laishi, Wantai Bio, and Bid Pharma also experiencing gains [1] - Trump previously announced that drug tariffs could reach as high as 200% [1]

Group 1 - The ChiNext Index initially increased by 1%, while the Shanghai Composite Index rose by 0.15% [1] - The large healthcare sector experienced a collective rebound, with strong performance in CRO, innovative drugs, monoclonal antibodies, and recombinant proteins [1] - Approximately 3,800 stocks in the market rose, while 1,300 stocks declined, indicating a net outflow of over 2 billion yuan from major funds [1]

Core Viewpoint - The trading volume in the Shanghai and Shenzhen markets exceeded 1 trillion, showing a decrease of approximately 200 billion compared to the same trading day of the previous period [1] Market Performance - The Shanghai Composite Index fell by 0.03%, while sectors such as electricity, diversified finance, and real estate showed notable gains [1] - Approximately 2,900 stocks rose, while 2,200 stocks declined, indicating a mixed market sentiment [1] - There was a net outflow of over 15 billion in principal funds [1]